3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 1/2
1
Status
Recruiting
7
Terminated
2
Withdrawn
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
166
Docetaxel
154
Bevacizumab
153
Carboplatin
148
Gemcitabine
146
Cisplatin
146
pembrolizumab
144
Radiotherapy
135
Paclitaxel
132
Capecitabine
122
Rituximab
115
Oxaliplatin
104
Fluorouracil
103
Nivolumab
94
Irinotecan
85
Doxorubicin
85
Pemetrexed
83
Leucovorin
82
Dexamethasone
82
fludarabine
74
fludarabine phosphate
72
Bortezomib
69
Etoposide
67
Erlotinib Hydrochloride
66
Cetuximab
65
Methotrexate
58
Trastuzumab
56
Cytarabine
54
Lenalidomide
50
Everolimus
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Terminated
×
loncastuximab tesirine
×
Clear all
NCT05144009
2025-01-30
LOTIS-9
ADC Therapeutics S.A.
Phase 2
Terminated
41 enrolled
19 charts
NCT04699461
2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2
Terminated
6 enrolled
9 charts